Levamisole in rheumatoid arthritis. Final report on a randomised double-blind study comparing a single weekly dose of levamisole with placebo. Multicentre Study Group.
RESUMO
The therapeutic effect of a single weekly dose of levamisole in patients with rheumatoid arthritis was compared with placebo for 6 months in a 13-centre double-blind controlled study. 281 patients with classic or definite rheumatoid arthritis and active disease were evaluated. A single weekly dose of 150 mg levamisole was superior to placebo in controlling disease activity. A single weekly dose of 50 mg levamisole had an intermediate effect. Adverse reactions occurred in approximately 40% of the patients with 150 mg levamisole and in approximately 20% of the patients with 50 mg levamisole or placebo. In comparison with the classical dosage schedule of levamisole (150 mg on 3 consecutive days each week) a single weekly dose of 150 mg levamisole was found to be slightly less effective but much better tolerated.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1000901Documentos Relacionados
- Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.
- Postgonococcal urethritis: a double-blind study of doxycycline vs placebo.
- Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis.
- Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
- Treatment of nongonococcal urethritis with trimethoprim-sulphadiazine and with placebo. A double-blind partner-controlled study.
